Thank you very much, Mr. Chair, and I'll begin, and then turn it over to my colleagues on the specifics of clinical trials.
But it does strike me that there are two components in the question. One is what do the people who are in the clinical trials—and again one of the things that we look to as we inspect clinical trial sites will be things like informed consent and ensuring that there are the right mechanisms between the participants in the trial and the trial site, for example. So those are things that the individual patients in the trials can be assured of. Those are things that are part of our oversight requirements at clinical trials.
Then, with regard to the question about what citizens generally can know about clinical trials, as was mentioned, we've been encouraging all of the companies who have clinical trial sites in Canada to post them on international WHO-recognized websites, so that individuals can learn of those trials. That's one of the ways that people can understand it. Again, from our consultations, this summary document that we mentioned, people said this will be very helpful to understand, and we are continuing down the path of giving more information on specific trials as well.
Maybe now I'll turn it over to my colleagues.